Highlights

MediaPharma S.r.l.
A Company focused on the discovery and development of innovative drugs for the treatment of cancer and other diseases with unmet medical need.

MP-EV20/1959

Humanized bispecific antibody against HER3 and LGALS3BP

  • Humanized bispecific antibody against HER3 and LGALS3BP
  • Preclinical proof of efficacy established: inhibition of HER3 activation/downstream signaling in various tumor cell lines and inhibition of capillary-like structures in HUVEC
  • Indications in Oncology: cancers whose growth and progression depend on HER3 and LGALS3BP-promoted angiogenesis, including but not limited to those arising from breast, prostrate, ovary, lung, pancreas, stomach and melanoma.

I commenti sono chiusi.

Company

R&D

Careers

Business